Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Applied Biosystems

Qiagen this week released three new RNAi related products.
The first is the FlexiPlate siRNA, a line of 96-well plates in 0.1 nmol, 0.25 nmol, and 1 nmol scales for use with human or mouse target genes.
SiRNAs and controls, Qiagen said, can be selected and arranged on the plates using a Web-based interface.
The company has also released the HP OnGuard siRNA design algorithm.
The algorithm incorporates a neural-network algorithm and proprietary homology analysis, in addition to other new features including 3' UTR/seed region analysis, SNP avoidance, and interferon motif avoidance, Qiagen said.
Lastly, Qiagen introduced the Human Druggable Genome siRNA set 3.0, which targets more than 7,000 genes of therapeutic value. SiRNAs are available through the set either individually or in pools.

Applied Biosystems has introduced new TaqMan microRNA assays, including assays for human, mouse, Drosophila, and C. elegans genes.
The new assays are in addition to the company’s existing assays for rat and Arabidopsis genes and increase the complete TaqMan miRNA assay collection to 571.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.